Hepatitis G (GB Virus C) – Comprehensive Medical Guide

Overview

Hepatitis G, also known as GB virus C (GBV‑C), is a blood‑borne flavivirus that was first identified in the early 1990s. Unlike hepatitis A, B, C, D, and E, GBV‑C does not cause classic viral hepatitis, meaning it rarely leads to liver inflammation or damage. Instead, most infected individuals remain asymptomatic, and the virus is considered to have low pathogenicity.

Who it affects: GBV‑C is found worldwide, with higher prevalence among populations that have increased exposure to blood products:

• People who inject drugs (PWID)
• Recipients of blood transfusions before rigorous screening (pre‑1992 in many countries)
• Patients on long‑term hemodialysis
• Individuals with HIV or hepatitis C co‑infection

Prevalence: Estimates vary due to limited testing, but seroprevalence rates reported in different regions are:

• North America: 1–3 % in the general population; up to 15 % among PWID
• Europe: 2–6 % overall; 10–20 % in high‑risk groups
• Sub‑Saharan Africa and Southeast Asia: 5–10 % in the general adult population
• Global pooled prevalence (meta‑analysis, 2021): ≈ 3.3 % (doi:10.1186/s12879-021-06377-5)

Symptoms

Most people infected with GBV‑C never develop noticeable symptoms. When symptoms do appear, they are nonspecific and often overlap with other blood‑borne infections.

Commonly reported signs

• Fatigue – persistent tiredness not explained by other causes.
• Mild fever – low‑grade temperature (37.5–38.5 °C) lasting days to weeks.
• Headache – dull or throbbing, sometimes associated with fever.
• Myalgia – muscle aches, especially in the back and limbs.
• Joint pain – arthralgia without swelling.
• Transient rash – maculopapular eruptions, usually short‑lived.

Rare or atypical manifestations

• Elevated liver enzymes (ALT/AST) without clinical hepatitis.
• Mild lymphadenopathy (swollen lymph nodes).
• Occasional gastrointestinal discomfort (nausea, abdominal tenderness).

Because symptoms are vague, GBV‑C infection is often discovered incidentally during screening for other infections (e.g., HIV, hepatitis C).

Causes and Risk Factors

GBV‑C is transmitted primarily through exposure to infected blood. The virus does not replicate in the gastrointestinal tract, so fecal‑oral spread (as seen with hepatitis A/E) is not a concern.

Transmission routes

• Injection drug use – sharing needles or syringes is the most efficient mode.
• Blood transfusion – especially before universal nucleic‑acid testing (NAT) of blood donors.
• Organ transplantation – donor organs may carry the virus.
• Occupational exposure – needlestick injuries among healthcare workers.
• Sexual contact – possible but appears to be a low‑efficiency route.
• Mother‑to‑child – rare vertical transmission during childbirth.

Risk factors

• History of injection drug use or participation in needle‑sharing networks.
• Receiving blood products before the early 1990s.
• Chronic kidney disease requiring hemodialysis.
• Co‑infection with HIV or hepatitis C, which share transmission pathways.
• Occupational exposure in settings with high‑volume blood handling.

Diagnosis

Because routine clinical testing for GBV‑C is not widely available, diagnosis is usually reserved for research or for patients with unexplained serologic findings.

Laboratory tests

1. Serology (anti‑GBV‑C antibodies) – Detects immune response indicating past or current infection. Enzyme‑linked immunosorbent assay (ELISA) kits are used in specialized labs.
2. RNA detection (RT‑PCR) – Confirms active viremia by amplifying viral RNA from plasma. This is the gold standard for current infection.
3. Quantitative viral load – Measures copies/mL of GBV‑C RNA, useful for research on co‑infection dynamics.

Interpretation

• Positive antibodies + negative PCR: past exposure, no active virus.
• Positive PCR (with or without antibodies): active infection.
• Co‑testing for hepatitis B, hepatitis C, and HIV is recommended because of overlapping risk factors.

Other evaluations

Routine liver function tests (ALT, AST, bilirubin) are often normal. If abnormalities are present, clinicians must rule out other hepatic diseases.

Treatment Options

To date, **no antiviral therapy specifically targets GBV‑C**, and the virus generally does not cause clinically significant disease. Management focuses on monitoring and addressing co‑existing conditions.

Medical approach

• Observation – Periodic testing (every 6–12 months) for viral load if the patient has HIV or hepatitis C, as GBV‑C may influence disease progression.
• Antiretroviral therapy (ART) for HIV – Studies suggest that effective HIV suppression may also reduce GBV‑C replication.
• Hepatitis C treatment – Direct‑acting antivirals (DAAs) for HCV do not eradicate GBV‑C, but treating HCV improves overall liver health.

Potential future therapies

Research is ongoing to determine whether GBV‑C could be harnessed as a therapeutic agent because some data suggest it may slow HIV progression. No clinical use is approved.

Lifestyle and supportive care

• Avoid further blood exposure (e.g., safe injection practices).
• Maintain a healthy diet and regular exercise to support immune function.
• Vaccinate against hepatitis A and B (no vaccine exists for GBV‑C).

Living with Hepatitis G (GB Virus C)

For most individuals, living with GBV‑C does not require major lifestyle changes, but certain habits can help keep overall health optimal.

Practical daily‑management tips

• Stay informed – Keep a copy of your lab results and discuss any changes with your healthcare provider.
• Practice safe injection techniques – If you use drugs, use sterile needles, consider needle‑exchange programs, or seek medication‑assisted treatment.
• Regular medical follow‑up – Annual check‑ups that include liver function tests and HIV/HCV screening.
• Limit alcohol – Alcohol can strain the liver; even though GBV‑C rarely harms the liver, minimizing alcohol reduces overall risk.
• Nutrition – A balanced diet rich in fruits, vegetables, lean protein, and whole grains supports immune health.
• Stress management – Chronic stress can weaken immunity; consider mindfulness, yoga, or counseling.

Because GBV‑C rarely causes disease, most patients can continue normal work, school, and recreational activities. However, they should inform sexual partners and healthcare providers about their infection status.

Prevention

Since GBV‑C spreads through blood, preventive strategies parallel those for hepatitis C and HIV.

Primary prevention measures

• Never share needles or syringes – Use a new, sterile needle for every injection.
• Safe medical practices – Ensure that any blood transfusion, organ transplant, or invasive procedure follows strict sterile protocols.
• Universal precautions – Healthcare workers should wear gloves, use safety‑engineered sharps, and follow post‑exposure prophylaxis (PEP) guidelines if needed.
• Barrier protection – While sexual transmission is uncommon, using condoms reduces any possible risk.
• Screening of blood donors – Modern blood banks employ NAT testing that detects GBV‑C, further lowering transfusion risk.

Vaccination

No vaccine exists for GBV‑C, but vaccination against hepatitis A and B is recommended for all adults, especially those at higher risk for blood‑borne infections.

Complications

GBV‑C infection is generally benign, yet certain scenarios may lead to complications:

• Co‑infection with HIV – Some studies suggest GBV‑C may slow HIV disease progression, but data are mixed; careful monitoring is required.
• Co‑infection with hepatitis C – Dual infection can complicate liver disease assessment; however, GBV‑C itself does not increase liver damage.
• Potential immune modulation – Rare reports link GBV‑C to altered cytokine profiles, which could affect autoimmune conditions, though causal relationships are not established.
• Rare progression to severe fatigue or chronic pain – In a small subset, persistent fatigue can impact quality of life.

Overall, the risk of serious organ damage or death directly from GBV‑C is extremely low.

When to Seek Emergency Care

References

• Mayo Clinic. “Hepatitis C.” https://www.mayoclinic.org/diseases-conditions/hepatitis-c
• Centers for Disease Control and Prevention. “Bloodborne Pathogens.” https://www.cdc.gov/bloodsafety
• World Health Organization. “Global Hepatitis Report 2023.” https://www.who.int/publications/i/item/9789240061158
• Cleveland Clinic. “HIV and Co‑Infections.” https://my.clevelandclinic.org/health/diseases/17785-hiv
• Garcia‑Manuel, J. et al. “Epidemiology of GB Virus C: A systematic review.” *BMC Infectious Diseases*, 2021;21:345. https://doi.org/10.1186/s12879-021-06377-5
• Huang, Y. et al. “GB virus C infection and its impact on HIV progression.” *Journal of Viral Hepatitis*, 2020;27:102–110.